Comprehensive one-stop drug development.
About Us
Your Partner in Cutting-Edge MyD88-Targeted Solutions
As a leading research service provider, we leverage advanced technology and innovative solutions to drive MyD88-targeted drug and therapy development.
-
-
Accelerated timelines with our pipeline.
-
Advanced facilities ensure precision and reliability.
-
Experienced team specialized in MyD88 research.
Services
What We Offer
We provide comprehensive MyD88-targeted solutions, covering the entire drug development process from discovery to clinical trials, including IIT services to accelerate the development of innovative therapeutics.
Featured Services
Therapeutic Discovery
Accelerating therapeutic breakthroughs with innovative discovery solutions tailored to your research needs.
Diseases Models
Building reliable disease models to enhance preclinical research accuracy and predictability.
Pharmacokinetics
Optimizing drug metabolism and pharmacokinetics to improve safety and efficacy profiles early in development.
Drug Safety Evaluation
Ensuring comprehensive safety evaluations to support regulatory submissions and mitigate potential risks.
IIT Services
Supporting investigator-led trials with end-to-end assistance to advance innovative therapies.
PLATFORMS
Discover Therapeutics
Our platform specializes in the development of diverse therapeutic modalities to address complex MyD88-targeted challenges with precision and innovation.
Small Molecule Inhibitors
Harnessing targeted small molecule inhibitors to modulate MyD88 signaling with precision and efficacy.
Monoclonal Antibodies
Developing high-affinity monoclonal antibodies for specific MyD88 pathway intervention across various disease areas.
siRNA
Utilizing siRNA technology to silence MyD88 expression, offering a novel approach in targeted treatment strategies.
Mimetic Peptides
Creating mimetic peptides that replicate natural MyD88 interactions, paving the way for innovative therapeutic solutions.
Pipelines
MyD88 Focus
Designed with a strong focus on MyD88-targeted therapies, our pipeline addresses key pathways to drive therapeutic innovation and is open for technology transfer or strategic partnerships.
TLR/MyD88 Inhibitor for Psoriasis
Focused on targeting key pathways in psoriasis, this inhibitor offers a novel approach to managing inflammation.
IRI Emergency IV Therapy
Designed for ischemia-reperfusion injury in acute myocardial infarction, this IV therapy minimizes tissue damage.
Oral Tablets for Colitis & Colorectal Cancer
This oral formulation addresses inflammatory and oncological pathways in colitis and colorectal cancer.
Metabolic Disorders Oral Tablets
This product targets metabolic pathways, offering solutions for diabetes, obesity, and fatty liver disease.
SLE Oral Therapy
This oral therapy is tailored to modulate autoimmune pathways in systemic lupus erythematosus.
Transplant Rejection Therapy (Oral/IV)
This therapy supports immune modulation in organ transplant settings, available in oral and IV forms.
WE PROVIDE EXCEPTIONAL SOLUTIONS
Advancing Therapeutics with Precision and Innovation
With our expertise in MyD88-targeted platforms, we deliver comprehensive solutions to meet your research and development
needs, ensuring reliable results at every stage.